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Diabetic nephropathyDiabetic nephropathy is one of the main causes of end-stage renal disease, in which the development of
tubular damage depends on factors such as high glucose levels, albuminuria and advanced glycation end-
product. In this study, we analyzed the involvement of heparanase, a heparan sulfate glycosidase, in the
homeostasis of proximal tubular epithelial cells in the diabetic milieu. In vitro studies were performed on a
wild-type and stably heparanase-silenced adult tubular line (HK2) and HEK293. Gene and protein expression
analyses were performed in the presence and absence of diabetic mediators. Albumin and advanced glycation
end-product, but not high glucose levels, increased heparanase expression in adult tubular cells via the AKT/
PI3K signaling pathway. This over-expression of heparanase is then responsible for heparan sulfate reduction
via its endoglycosidase activity and its capacity to regulate the heparan sulfate-proteoglycans core protein. In
fact, heparanase regulates the gene expression of syndecan-1, the most abundant heparan sulfate-
proteoglycans in tubular cells. We showed that heparanase is a target gene of the diabetic nephropathy
mediators albumin and advanced glycation end-product, so it may be relevant to the progression of diabetic
nephropathy. It could take part in several processes, e.g. extracellular-matrix remodeling and cell–cell
crosstalk, via its heparan sulfate endoglycosidase activity and capacity to regulate the expression of the
heparan sulfate-proteoglycan syndecan-1.nd Dialysis, Columbus-Gemelli
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End-stage renal disease (ESRD) is increasing in western countries
and diabetic nephropathy (DN) is one of the most frequent causes [1].
The pathophysiological changes in DN include glomerular hyperﬁl-
tration, abnormal permeability of the glomerular sieve to albumin,
and cellular and extracellular changes in the glomerulus and tubulo-
interstititium, which lead to a worsening renal function and
ultimately to ESRD [2]. As in most chronic renal diseases, even if the
primary damage is restricted to the glomerulus, the renal tubule and
interstitium become more and more involved as the disease pro-
gresses. It is now recognized that the stage of disease and its prognosiscorrelate better with the severity of tubulo-interstitial damage than
with glomerular sclerosis [3,4].
In diabetes, tubular injury in the kidney is due to several factors,
particularly high glucose levels, albuminuria, and the presence of
advanced glycation end-product (AGE)-modiﬁed proteins. Exposure
of the proximal tubular epithelial cells (PTECs) to high albumin
concentrations and AGE-modiﬁed proteins leads to the activation of
multiple signaling cascades, with an ensuing abnormal regulation of
several growth factors and cytokines, and an abnormal synthesis and
degradation of extracellular matrix (ECM) proteins, giving rise to a
pro-ﬁbrotic environment distinctive of the failing kidney [5–7].
Recent ﬁndings suggest an involvement of glomerular heparanase-1
(HPSE) in the pathogenesis of proteinuric disorders, including DN [8].
HPSE is a heparan sulfate (HS)-speciﬁc endo-β-D-glucuronidase that
catalyzes the hydrolytic cleavage of theβ(1,4)-glycosidic bond between
glucuronic acid and glucosamine residue. HPSE participates in ECM
remodeling and degradation, regulating the release ofmanyHS-bonded
molecules, such as growth factors, chemokines, cytokines, and enzymes
involved in inﬂammation, wound healing and tumor invasion. Hepar-
anase is expressed in numerous cell types and tissues, and it is
abundantly expressed by several different tumor cells. Its expression
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may have non-enzymatic activities, playing a part in different signaling
cascades, selected protein kinase activation, and gene transcription [11].
While HPSE has been investigatedmainly in the glomeruli, when it
comes to the renal tubule we only know that its tubular expression is
found increased in biopsies from patients with DN and this correlates
with a decline in HS tubular staining [12]. Given the crucial role of
tubular cells in the progression of DN, we thoroughly investigated the
effect of the diabetic milieu on HPSE regulation in the tubular cell, and
its consequences downstream. In particular, we analyzed: the effect of
high glucose, albumin and glycated albumin levels on the expression,
synthesis and activity of HPSE; the signaling pathways involved; the
effect of an altered HPSE expression on HS and the above
mechanisms; and the interaction between HPSE, HS and syndecan-1
(SDC1), which is the most abundant HSPG in the proximal tubule.
2. Methods
2.1. Cell cultures
HK2 (humankidney 2) is an immortalizedproximal tubule epithelial
cell line whereas HEK293 is a human embryonic tubular cell line. HK2
cells were grown in DMEM-F15 (EuroClone, Pavia, Italy) (17.5 mM
glucose) and HEK293 cells in MEM (EuroClone), supplemented
with 10% fetal bovine serum (Biochrom AG, Berlin, Germany), 2 mM
L-glutamine, penicillin (100 U/ml) and streptomycin (100 μg/ml), and
maintained at 37 °C in a 5% CO2 water-saturated atmosphere.
2.2. Reagents
Bovine serum albumin (BSA, Sigma, Milano Italy), D-(+)-glucose
and D-(+)-mannitol (Sigma), NF-kB inhibitor ammonium pyrrolidine
dithiocarbamate (PDTC, Sigma), PI3 kinase inhibitor LY294002, p38
kinase inhibitor SB203580, Jak2 inhibitor AG490, MEK1 and MEK2
inhibitors PD98059 and U0126 (Calbiochem, San Diego, USA) were all
purchased commercially. Sulodexide was a kind gift from Alfa
Wassermann, Bologna, Italy.
2.3. Preparation of albumin-derived AGE
BSA-derived AGE was prepared by incubating 0.5 M glucose with
20 mg/ml BSA and 0.05 mg/ml NaN3 in 0.4 M phosphate buffer (pH 7.5)
for 15 days at 56 °C under sterile conditions. After incubation, unbound
glucose was removed by dialysis against phosphate buffer. AGE protein
concentration was evaluated using the Bio-Rad Protein Assay (Bio-Rad,
Milan, Italy). Themixture turned into a stable viscous brownproduct that
yielded ﬂuorescence of 440 nm following excitation at 370 nm. The
control BSA sample (non-glycated BSA) was incubated under identical
conditions, butwithout any glucose. AGE and control (non-glycated BSA)
wereﬁlter sterilized, aliquotedandstoredat−20 °Cuntil theywereused.
2.4. Transfection of HPSE shRNA plasmid
To obtain stably HPSE silenced cell lines, we used four different
shRNAs targeting human heparanase (NM_006665), purchased from
OriGene (Rockville, MD, USA). We performed a transfection reaction for
each plasmid, plus a reaction in which all four plasmids have been
transfected together. As a negative control, we used an shRNA pRS non-
effective GFP plasmid (TR30003) and an empty vector, shRNA pRS
plasmid (TR20003). The shRNAswere reconstitutedwith 50 μl of RNAse-
free water (Gibco, Invitrogen, Milano, Italy) to prepare a 100 ng/μl stock
solution. HK2 cells were seeded in 6-well plates at a density of 1.5×105
cells perwell. After 24 h, the cells had reached 70–80% of conﬂuence. The
mediumwas removed and replacedwith twomilliliters per well of fresh
complete growthmedium. Amixture preparedwith 188 μl of serum free
medium and 12 μl of TransIT-LT1 transfection reagent (Mirus, Madison,WI) was vortexed and incubated at room temperature for 20 min. Three
microgramsof plasmidsDNAwere added to themixture,whichwas then
incubated at room temperature for another 20 min before adding it
dropwise to the cells. Control cellswere treatedwith the same amount of
TransIT-LT1 transfection reagent (Mock). Forty-eight hours after trans-
fection, the cells underwent severalweeks of selectionwith 0.75 μg/ml of
puromycin (Sigma).
2.5. Transfection of AKT1/2 siRNA
To silence AKT1 and AKT2 we use AKT1/2 siRNA (sc43609, Santa
Cruz Biotechnology Heidelberg, Germany) as well as a control si-RNA.
The siRNAs were reconstituted with 330 μl of RNAse-free water to
prepare a 100 μM solution. HK2 wt cells were plated in 6-well plates
at a density of 1.5×105 cells per well in 2 ml complete growth
medium. After 24 h, we prepared a mixture with 188 μl of serum-free
medium and 12 μl of TransIT-LT1 transfection reagent (Mirus). The
solution was vortexed and incubated at room temperature for 20 min,
then we added 6.6 μl of siRNAs and the mixture was then incubated at
room temperature for another 20 min before adding it dropwise to
the cells. After 24 h the medium was replaced with fresh complete
growth medium. Cells were incubated for an additional 24 h and then
starved, treated with BSA and AGE and assayed for HPSE gene
expression and AKT protein expression described as follows.
2.6. mRNA expression analysis
The cells were grown to sub-conﬂuence, starved for 24 h in serum-
free medium, and then cultured in serum-free medium with the
different treatments for another 6 h.
The cells were exposed to normal glucose (17.5 mM), a high
mannitol as an osmolarity control (25 mM), high glucose levels
(25 mM), and BSA or AGE (30 or 60 μg/ml), with or without the
inhibitors: LY294002 (25 μM), SB203580 (20 μM), PD98059 (25 μM),
U0126 (10 μM), AG490 (25 μM) and PDTC (10 μM). All these
inhibitors were added 30 min before the BSA and AGE treatments,
except for LY294002 (which was added 2 h beforehand).
Total RNAwas extracted from cell monolayers using the “GenElute
Mammalian Total RNA Miniprep” Kit (Sigma), including DNAse
treatment (DNASE70, Sigma), according to the manufacturer's in-
structions. Yield and purity were checked using Nanodrop (Euro-
Clone) and 1 μg of total RNA from each sample was reverse
transcribed into cDNA using 500 ng random primers and 200 U
SuperScript II Reverse Transcriptase (Invitrogen).
Then we performed a quantitative real-time PCR to measure HPSE,
SDC1 or GAPDH expression. The assays were performed on 96multi-well
PCR plates in the Applied Biosystems 7500 real-time PCR system, in a
ﬁnal volume of 12.5 μl containing 10 ng of cDNA, 6.25 μl of Power SYBR
Green Master Mix 2× (Applied Biosystems, Carlsbad, USA), 5 μmol of
forward or reverse primers (HPSE: d—ATTTGAATGGACGGACTGC r—
GTTTCTCCTAACCAGACCTTC; SDC1: d—GAAGATCAAGATGGCTCTGGG r—
GTTCTGGAGACGTGGGAATAG; GAPDH: d—ACACCCACTCCTCCACCTTT
r—TCCACCACCCTGTTGCTGTA), and water q.s. The reaction underwent
denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation
at 95 °C for 30 s, annealing and elongation at 60 °C for 1 min.
mRNAexpression levelswereevaluatedby relative quantitative real-
time PCR and normalized toGAPDH. The comparative Ctmethod (ΔΔCt)
was used to quantify gene expression and the relative quantiﬁcation
(RQ)was calculated as 2−ΔΔCt.We performedmelting curves analysis to
avoid any interference of aspeciﬁc ampliﬁcation products.
2.7. Western blot
To analyzeHPSE andGAPDHprotein expression, cellswere grown to
subconﬂuence for 24 h in serum-free medium, then washed with PBS,
lysed and scraped in lysis buffer (50 mM Tris–HCl [pH 5.0], 150 mM
Fig. 1. Real-time PCR quantiﬁcation of HPSE mRNA expression in tubular cells. HPSE
mRNA expression levels in wt (black bars) and silenced (white bars) HK2 cell lines
were determined by real-time PCR. The results were normalized using GAPDH as the
internal control and represent the mean±standard deviation of three separate
experiments performed in triplicate (**pb0.001 vs. wt).
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(Roche, Milan, Italy) and the phosphatase inhibitor cocktails 1 and 2
(Sigma). To analyze AKT and pAKT, 24-hours serum-starved cells were
treated for 20 min with BSA and AGE (60 μg/ml) and then lysed. Cell
lysateswere sonicated, centrifuged at 4 °C for 30 min at 15,000g and the
total protein in the supernatant was quantiﬁed using the Bio-Rad
Protein Assay. Total proteins (50 μg) were treated in reducing sample
buffer (2% SDS, 80 mM Tris–HCl [pH 6.8], 10% glycerol, 0.005%
bromophenol blue, 10% ß-mercaptoethanol) and denatured for
10 min at 100 °C. Then samples were separated in 10% SDS–PAGE
(120 V–25 mA) and electro-transferred to nitrocellulose membranes
(300 V–350 mA) for 2.5 h at 4 °C. Non-speciﬁc binding was blocked for
1 h at room temperature with fat-free milk (5%) in TBST buffer (20 mM
Tris–HCl [pH 7.4], 150 mM NaCl, 0.05% Tween-20).
Membranes were exposed to primary polyclonal antibody anti-
HPSE, anti-GAPDH, anti-AKT and pAKT (sc-25825, sc-25778, sc-8312
and sc-7985-R, respectively, Santa Cruz Biotechnology) overnight at
4 °C and after washing three times in TBST buffer, the membranes
were incubated for 1 h with a secondary peroxidase-conjugated
antibody (sc-2004, Santa Cruz Biotechnology, for HPSE and GAPDH
and NA934, Amershan, for AKT and pAKT) at room temperature.
The signal was detected using the “SuperSignals West Pico
Chemiluminescent” substrate solution (Pierce, Rockford, IL, USA),
according to the manufacturer's instructions.
2.8. Flow cytometry
Cells in the mid-log phase were cultured ﬁrst for 24 h in serum-
free medium, then for 48 h in serum-free medium with 0 or 60 μg/ml
of BSA or AGE, or 25 mM of D-(+)-glucose or D-(+)-mannitol, used as
an osmolarity control andwith or without 50 μg/ml of Sulodexide. The
cells were then harvested, washed with PBS, and ﬁxed. 5×105 cells
were incubated for 10 min in the dark with 0.5 μg of the primary
antibodies: anti-HS (monoclonal anti-HS, mouse IgM, k-chain, clone
HepSS-1; Seikagaku) [13] or syndecan-1 (mouse anti-human CD138,
clone MI15; BD Biosciences, Buccinasco, Italy) [14]. Isotype controls
were included in the analysis. Then the cells were washed three times
with PBS and incubated for 10 min in the dark with 0.5 μg of the
secondary antibodies, i.e. goat anti-mouse IgM-FITC (AbD Serotec,
Milano, Italy) or rat anti-mouse IgG-FITC (BioLegend, San Diego, USA).
Fluorescence was measured using a FACScan (BD).
2.9. Immunoﬂuorescence for syndecan-1
Cells were seeded in 22 mm glass dishes and cultured to
subconﬂuence, then washed twice with PBS and ﬁxed for 10 min in
4% PFA (prewarmed to 37 °C), and then permeabilized for 5 min at
room temperature in PBS with 0.2% Triton X-100. The cells were then
washed three times for 3 min with PBS and aspeciﬁc binding sites
were blocked by a 1-hour incubation in PBS with 1% BSA. Then the
cells were incubated for 1 h at room temperature with the primary
antibody (mouse anti-human CD138, clone MI15; BD Biosciences) in
PBS with 1% BSA (1:200), washed 3 times for 5 min with PBS, then
incubated for 1 h at room temperature with the secondary antibody
(rat anti-mouse IgG-FITC; BioLegend) in PBS with 1% BSA (1:100).
After another three washes with PBS, the nuclei were identiﬁed after
incubation for 5 min with 20 ng/ml of Hoechst.
2.10. HPSE detection by ELISA
HPSE activity in total cell lysates and cell culture supernatants was
quantiﬁed using the “Heparanase assay” Kit from AMS Biotechnology
(Milton Abingdon, Oxon, UK) according to the manufacturer's in-
structions. To prepare conditioned media, cells were starved for 24 h in
serum-free medium and then incubated other 24 h in serum-free
medium with 0 or 60 μg/ml of BSA or AGE. The media were thencollected and clariﬁed by centrifugation at 2000 g per 2 min. The plate
was incubated at room temperature for 30 min with 100 μl of PBS in
each well. The PBS was replaced with 50 μl of the reaction buffer. Each
well was ﬁlled with 50 μl of samples of conditioned serum-free media,
or 10 μg of total proteins prepared as described above. We used 50 μl of
reaction buffer as a negative control, and 50 μl of platelet protein extract
diluted 1:100 in 1× heparanase buffer as a positive control. The plate
was incubated for 1 h at 37 °C, then each well was washed 4 times with
PBT (PBS+0.1% vol./vol. Tween-20) and then twice with PBS. Finally,
100 μl of the Strep–HRP complex was added to each well and the plate
was incubated for 1 h at room temperature on a plate shaker. Themicro-
well plate was then washed 5 times with PBS before adding 100 μl of
peroxidase substrate at room temperature. The platewas shaken gently
and the absorbance was measured at 450 nm in an ELISA plate reader.
The activity of each sample was calculated as explained by the
manufacturer and given in nanograms of HS removed per minute.
2.11. Statistics
The standard deviations and statistical analyses of the real-time PCR
data were calculated using the Rest 2009 software. For the analysis of
the ﬂow cytometry data and KS evaluation we used the corresponding
FACScan software (BD). Differences between wild-type and HPSE
silenced cells, or treated and untreated cells, were compared using
Student's t-test. A p value≤0.05 was considered signiﬁcant for all tests
3. Results
3.1. Stable HPSE silencing of the HK2 cell line
To investigate the role of HPSE expression in proximal tubular
cells, we down-regulated HPSE in an HK2 cell line. From each 29 mer-
shRNA targetingHPSEmRNA and the corresponding negative controls,
we obtained different clones under puromycin selection. We
evaluated HPSE mRNA expression in all clones by real-time PCR
analysis. HPSE expression did not differ in wild type (wt) cells or
clones transfected with the negative control plasmids (data not
shown). Among the silenced clones, the two with the best silencing
rate (shRNA1 and shRNA2) were chosen for subsequent experiments.
The shRNA1 clone was obtained by transfecting the cells with all four
29 mer-shRNA plasmids; the shRNA2 by transfecting them with
pHPSE-3. The gene knockdown was 96% and 80% in the shRNA1 and
shRNA2 clones, respectively (Fig. 1).
Fig. 2. Detection of HPSE protein. Western blot analysis was used to demonstrate HPSE
protein reduction between wt (black bars) and silenced (white bars) HK2 cell lines.
GAPDH was included as the loading control. Bottom: quantitative analysis of three
separate experiments (**pb0.01 vs. wt).
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analysis of the bands obtained by Western blotting and GAPDH-
normalized in total cell lysates revealed a 42% and 55% reduction in
clones shRNA1 and shRNA2, respectively (Fig. 2).
Since HPSE undergoes a complex and strictly regulated post-
transcriptional processing, we also evaluated HPSE activity in wt and
silenced HK2 cell clones. We used an ELISA assay to test total cell
lysates and conditioned media from wt and shRNA1 HK2 cell lines,
ﬁnding a signiﬁcant reduction in HPSE activity, in total cell lysates and
conditioned media, respectively (Fig. 3).Fig. 3. Detection of HPSE activity. Heparanase activity in protein extracts (A) and serum-
free conditionedmedium (B) obtained fromHPSE-silenced-HK2, HK2wt and HEK293 cell
lines. Cellswere treatedwith 60 μg/ml of BSA or AGE (hatchedbars) in serum freemedium
(black bars). Enzymatic activity is expressed as nanograms of heparan sulfate (HS)
removed perminute. The results represent themean±standard deviation of two separate
experiments performed in triplicate. Platelet extract was used as a positive control (white
bar) (*pb0.05, **pb0.001 vs. HK2 wt control; #pb0.05, ##pb0.001 vs. HEK293 control).3.2. HPSE expression in PTECs is regulated by BSA and AGE, but not by
high glucose levels
We performed a relative quantitative real-time PCR analysis on
HK2 and HEK293 cell lines to evaluate HPSE expression levels in
response to different “diabetic stimuli,” such as high glucose levels,
albumin overload and glycated albumin.Fig. 4. HPSE regulation in tubular cells. HPSE mRNA expression levels in control (black
bars) and treated (white and hatched bars) HK2 wt (A), HEK293 (B) and silenced HK2
(C) cell lines were determined by real-time PCR. Cells were cultured for 6 h under
normal glucose concentrations (NG: 17.5 mM glucose), with highmannitol levels as the
osmolarity control (OC: 25 mM mannitol), with high glucose levels (HG: 25 mM
glucose), and with BSA or AGE (30 or 60 μg/ml). The results were normalized using
GAPDH as the internal control and represent the mean±standard deviation of three
separate experiments performed in triplicate (*pb0.05, **pb0.001 vs. control).
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did not affect HPSE gene expression, whereas treatment with BSA—and
evenmore with glycated albumin—triggered a dose-dependent increase
inHPSE expression. Inparticular, 30 and60 μg/mlof BSA induced1.7- and
2.8-fold increases, respectively, while 30 and 60 μg/ml of AGE induced a
3.6- and 4.1-fold increase, respectively, in HK2wt cells (Fig. 4A). BSA and
AGE, likewise, induced a signiﬁcant increase of HPSE expression in
HEK293 cells, respectively, of 1.68 and 2.81 times (Fig. 4B).
The same experiment was conducted in HPSE silenced clones. High
glucose levels (and the osmolarity condition used as a control) did not
affectHPSEgeneexpression, not even in theHPSEsilenced clones.Unlike
the situation inwt HK2 cells, however, BSA and AGE failed to induce any
signiﬁcant variation in HPSE expression in HPSE silenced cells (Fig. 4C).
Likewise, the gene expression proﬁle BSA and AGE also modiﬁed
HPSE activity both at the intracellular and extracellular level. As amatter
of fact BSA, and mostly AGE, produced an increase of HPSE activity in
HK2 wt and HEK293 protein extract and conditioned media,whereas
they had no effects on HPSE-silenced HK2 cells (Fig. 3A and B).
3.3. BSA and glycated albumin regulate HPSE expression via the
PI3K/AKT pathway
To investigate the signaling pathways involved in modulating HPSE
synthesis by BSA and glycated albumin, we incubated cells with theFig. 5. Signaling pathways analysis involved in HPSE up-regulation. A) HPSE gene expression
(hatched bars). mRNA levels were determined by real-time PCR. The wt HK2 cells were prei
(25 μM), U0126 (10 μM), AG490 (25 μM) and PDTC (10 μM), then cultured with 60 μg/ml
control and represent themean±standard deviation of three separate experiments performe
B)Western blot analysis was used to quantify total AKT and pAKT protein in wt and AKT1/2-s
analysis of two separate experiments. C) HPSE gene expression in wt and AKT-silenced HK
(hatched bars). Results were normalized using GAPDH as an internal control and represent th
wt cells treated with BSA or ##pb0.001 vs. wt cells treated with glycated albumin).following different kinase inhibitors: the NF-kB inhibitor PDTC (10 μM),
the PI3 kinase inhibitor LY294002 (25 μM), the p38 kinase inhibitor
SB203580 (20 μM), the Jak2 inhibitor AG490 (25 μM), the MEK1
inhibitor PD98059 (25 μM) and the MEK1-2 inhibitor U0126 (10 μM).
Our results showed thatonly the LY294002(thePI3K inhibitor)wasable
to fully inhibit the increase in HPSE levels in wt HK2 cells treated with
BSA or glycated albumin. We also observed that PDTC (the NF-kB
pathway inhibitor), AG490 (the Jak2pathway inhibitor) andU0126 (the
MEK1-2/ERK pathway inhibitor) upregulated heparanase expression in
control wt HK2 cells (not incubated with BSA or glycated albumin)
(Fig. 5A). To elucidate the role of PI3K/AKT pathway in HPSE regulation
we silenced AKT. We silenced the two isoforms AKT1 and AKT2
obtaining a signiﬁcant decrease of AKT total protein. The stimulation
with albumin and especially with AGE produced a consistent activation
of AKT in wt cells whereas in AKT1/2-silenced HK2 cells these factors
induced aweaker phosphorylation of this kinase (Fig. 5B). The silencing
of AKT, like the PI3K inhibitor, prevents HPSE gene expression up-
regulation in response to BSA and AGE (Fig. 5C).
3.4. Cell-surface HS degradation by HPSE in PTECs
To investigate the effect of different levels of HPSE expression
on cell-surface HS expression, we examined cell-surface HS in wt
vs. HPSE silenced HK2 cell lines by ﬂow cytometry. We used ain control (black bars) wt HK2 cell line and those treated with BSA or glycated albumin
ncubated with different inhibitors, i.e. LY294002 (25 μM), SB203580 (20 μM), PD98059
BSA or glycated albumin for 6 h. Results were normalized using GAPDH as an internal
d in triplicate (**pb0.001 vs. cells treated with BSA or ##pb0.001 vs. glycated albumin).
ilenced HK2 cell lines. GAPDHwas included as the loading control. Bottom: quantitative
2 cells, control (black bars) and treated with 60 μg/ml BSA or glycated albumin for 6 h
e mean±standard deviation of two experiments performed in triplicate (**pb0.001 vs.
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closely related to 0-sulfated and N-acetylated glucosamine (clone
HepSS-1). Cell-surface HS was signiﬁcantly higher in the shRNA1 and
shRHA2 clones respect to HK2 wt cells. To see how the different
“diabetic stimuli” affect HS expression, we treated wt and silenced
cells for 24 h with high mannitol levels as an osmolarity control
(25 mM), high glucose levels (25 mM), or BSA or AGE (60 μg/ml).
While high glucose levels and the osmolarity control had no effect on
HS in any of the cell lines investigated (data not shown), BSA and
particularly AGE prompted a signiﬁcant reduction in HS in wt HK2
cells, but not in HPSE silenced clones (Fig. 6A). To assess the
contribution of HPSE-endoglycosidasic activity to HS degradation
we also incubated HK2wt cells with orwithout Sulodexide (50 μg/ml)
as HPSE-inhibitor [15]. The treatment with Sulodexide had no effects
on control cells while it partially increased HS staining in BSA- and
AGE-treated cells, though it failed to restore this to levels comparable
with those in untreated wt cells (Fig. 6B).
3.5. Syndecan-1 regulation by HPSE in PTECs
To investigate whether cell-surface HS reduction depends on HPSE
cleavage of the carbohydrate chains alone, or whether HPSE also
regulates the core protein synthesis of HSPGs, we analyzed syndecan-1,
the most abundant cell membrane HSPG in PTECs.
To quantify the total amount of syndecan-1, we performed a ﬂow
cytometric analysis using an anti-syndecan-1 monoclonal antibody
that speciﬁcally recognizes the core protein (clone MI15). Our
ﬁndings showed a signiﬁcant increase in cell-surface syndecan-1 inFig. 6. Analysis of HS regulation. A) Cell-surface HS expression in wt (black bars) and
silenced (gray bars) HK2 cells, and in those treated with 60 μg/ml BSA or AGE (hatched
bars), investigated by ﬂow cytometry. B) Cell-surface HS expression in wt HK2 cells
incubated in control media with 60 μg/ml BSA or AGE and treated (white bars) or
untreated (black bars) with 50 μg/ml of the HPSE inhibitor Sulodexide. The results
represent the mean±standard deviation of two separate experiments performed in
triplicate (*pb0.05, **pb0.001 vs. control wt cells).both the HPSE silenced clones. As in the case of HS, while high glucose
levels and the osmolarity control had no effect on syndecan-1 in wt or
HPSE silenced cell lines (data not shown), BSA and AGE both
prompted a signiﬁcant syndecan-1 protein reduction in wt HK2
cells, but not in HPSE silenced clones (Fig. 7A).
We conﬁrmed the greater amount of syndecan-1 in HPSE silenced
cells by immunoﬂuorescent staining too. The wt HK2 cells showed a
prevalent nuclear syndecan-1 staining, while the HPSE silenced cells
stained more intensely at both nuclear and cytoplasmic levels (Fig. 7B).
To establishwhetherHPSE regulates syndecan-1 at transcriptional or
post-transcriptional level, we used real-time PCR to assess syndecan-1
gene expression inwt andHPSE silenced clones. By comparisonwith the
wt HK2 cells, both the shRNA1 and the shRNA2 clones had a signiﬁcant
gene upregulation. Neither high glucose levels nor the osmolarity
control had any effect on syndecan-1mRNA expression in any of the cell
lines (datanot shown). Inmuch the samewayasat theprotein level, BSA
and glycated albumin determined a signiﬁcant syndecan-1 gene
downregulation in wt HK2 cells, but had no effect on syndecan-1
mRNA regulation inHPSE silenced clones (Fig. 7C). BSAandAGE exerted
the same effects on HEK293 cells producing signiﬁcant decrease of
syndecan-1 gene expression, respectively, of 22 and 51% (Fig.7D).
4. Discussion
Glomerular heparanase is an interesting player in the arena of
proteinuric disease and several investigators have shown, in both
clinical studies and animal models, that HSPGs in the glomerular
basement membrane are severely reduced in DN and that HS is
inversely correlated with glomerular HPSE expression. Little is known,
however, about its expression, regulation and role in PTEC, particularly
in diabetic conditions. The biology of PTEC is crucial to the development
and the rate of progression of DN, as in other renal diseases [16]. In this
study,wedemonstrate thatHPSE is a keymediator in thehomeostasis of
PTEC in the DN milieu, possibly playing a part in DN pathogenesis.
Our demonstration that HPSE is constitutively expressed in PTECs
suggests that it has a physiological role in the homeostasis of both
cells and ECM. In our cell model, HPSE is upregulated by mediators
involved in the pathogenesis of DN, and HPSE in turn affects a number
of pathways relevant to the pathogenesis of DN.
Unlike the case of the glomerular epithelial cells, high glucose
levels do not inﬂuence HPSE expression in PTEC; this means that, even
if podocytes and PTECs are cells with the same lineage, and they both
express glucose receptors [17,18], they have a different responsive-
ness and gene regulation.
High glucose levels do not cause any loss of HS, suggesting that high
glucose levels per se do not inﬂuence HS biosynthesis and turnover, or
HSproteoglycanexpression.Wecan reasonablymake this claimbecause
we used two speciﬁc antibodies in our experiments: one recognizing an
HS epitope closely related to N-acetylated, O-sulfated glucosamine
sensitive to O-desulfation, and one that selectively recognizes the core
protein of syndecan-1, a prototypic cell-membrane HSPG.
When a glomerular lesion becomes established in DN, the
glomerulus loses its permselectivity to proteins and a protein leak
consequently occurs, as reﬂected by proteinuria. Because of this protein
leakage through the glomerular barrier, the proximal tubular cells are
exposed to an array of proteins, particularly albumin and glycated
albumin. Incubation with these two proteins thus reproduces the
environment of DN, challenging the proximal tubular cells. Incubation
with albumin, and glycated albumin in particular, induces a dose-
dependent increase in HPSE expression in both tubular cell lines
analyzed. Moreover, these two substances produce an increment of the
HPSE HS-endoglycosidase-activity at the intracellular level and also in
the extracellular spaces. Thismeans that the increasedHPSE produced is
effectively released outside of the cells in the active form and it could be
able to perform its endoglycosidasic activity on tubular HS. This is the
ﬁrst demonstration that HPSE is a target of two paradigmaticmediators
Fig. 7. Analysis of syndecan-1 regulation. A) Syndecan-1 protein expressionwas detected by ﬂow cytometry inwt and silenced control (black bars)HK2 cells and in those treatedwith 60 μg/
ml BSA or AGE (hatched bars). The results represent the mean±standard deviation of three separate experiments performed in triplicate (**pb0.001 vs. control wt cells). B) Syndecan-1
protein localization was evaluated in wt and silenced cells by immunoﬂuorescence analysis: syndecan-1 was detected from the FITC-secondary antibody (green) and the nuclei were
counterstainedwithDAPI (blue). Thepictures arerepresentativeof three separateexperiments. Staining for syndecan-1 is stronger in theshRNA1clonethan in thewtHK2cells. C) Syndecan-1
mRNA expression levels inwt, silenced control (black bars) and treated (hatched bars) HK2 cells were determined by real-time PCR. Thewt and silenced cell lineswere culturedwith BSA or
AGE (0 or 60 μg/ml) for 6 h, and the results were normalized using GAPDH as the internal control. D) Syndecan-1 mRNA expression levels in HEK293 cells untreated (black bars) or treated
with 60 μg/ml of BSA or AGE (hatched bars). Gene expression results were normalized using GAPDH as an internal control and represent themean±standard deviation of two experiments
performed in triplicate (*pb0.05, **pb0.001 vs. control wt cells).
1481V. Masola et al. / Biochimica et Biophysica Acta 1813 (2011) 1475–1482of DN, albumin and glycated albumin.We investigated themechanisms
of these events and their effects downstream.
Albumin and AGE have been shown to activate several signal
pathways via a megalin-mediated uptake or RAGE interaction [6]. We
explored NF-kB, PI3 kinase, p38 MAPK, Jak and MEK1-2 downstream
signaling, testing the ability of speciﬁc inhibitors to reduce the
upregulation of HPSE expression triggered by albumin and glycated
albumin. Only the PI3K pathway was found to mediate the HPSE
upregulation induced by albumin and glycated albumin, since its
speciﬁc inhibitor LY294002 restored the HPSE expression to baseline
values. Xu et al. had already reported that AGE activates PI3K and its
downstream common effectors, AKT and ERK, in mesangial cells [19].
But in PTECs stimulated by glycated albumin (and albumin), the
downstream cascade only partially overlaps with the one observed in
mesangial cells because PD98059 and U0126, which inhibit MEK1-2
and thereby also the ERK pathways, failed to reduce the HPSE
upregulation triggered by albumin and glycated albumin.We therefore suggest that PI3K/AKT is the main signaling pathway
triggered by proteinuria and AGE, responsible for HPSE upregulation
in PTECs because these factors activate AKT, while silencing the AKT1
and AKT2, the two AKT isoforms reportedly activated in response to
albumin and advanced glycation end products [20,21], prevented the
HPSE upregulation by BSA and AGE. The PI3K/AKT pathway has
already been linked to heparanase, since it was shown that HPSE has
the ability to stimulate AKT in tumoral and endothelial cells [22].
Moreover, a recent study on human microvascular endothelial cells
(HMVEC) conﬁrmed that AGE induces HPSE expression, thus
underlying that an important diabetic mediator like AGE supervises
HPSE regulation in different tissues. However, the authors of this
study showed that HPSE expression is not PI3K-mediated in HMVEC,
suggesting that distinct pathway could focus on AGE-induced HPSE
regulation in different cellular types [23].
To investigate the effects of HPSE upregulation and distinguish them
from those caused directly by albumin and glycated albumin, we
1482 V. Masola et al. / Biochimica et Biophysica Acta 1813 (2011) 1475–1482generated an HK2 cell line that was stably silenced for HPSE. This
silenced cell line showed a signiﬁcantly reducedHPSEmRNAexpression
and protein level and also the HPSE activity were signiﬁcantly impaired
both in the cell lisates and in the extracellular ﬂuid. The apparent
discrepancies between the HPSE mRNA transcript, the cytoplasmic
amount of the HPSE protein and its activity in HPSE-silenced cells could
be reasonedby the fact that this enzymepresents a complexmechanism
of protein maturation, activation and secretion. Indeed, HPSE mRNA is
translated into an inactive protein precursor which is secreted, then it is
endocytosed andhence processed to form the active enzyme that can be
stored in vesicles or released in the extracellular space [11]. In theHPSE-
silenced cell line albumin and glycated albumin were unable to
upregulate HPSE gene expression and activity.
Our ﬁndings show that albumin and particularly glycated albumin
cause a signiﬁcant decrease in HS staining in wt tubular cells. These
results are in agreement with the greater HPSE expression and reduced
HS in the tubuli of renal biopsies from DN patients [12], pointing to a
negative regulation of HS levels byHPSE, as demonstrated in glomerular
cells. Otherwise in HPSE silenced cells the HS level was signiﬁcantly
increased, and treatment with albumin or glycated albumin had no
effect, suggesting that HPSE per se has a crucial role in determining HS
levels in tubular cells.
To prove whether the reduction in HS induced by albumin and AGE
depends on the increased endoglycosidase activity of HPSE we used an
HPSE inhibitor: Sulodexide, a glycosaminoglycan (GAG)-based drugs
composed of 80% heparin and 20% dermatan and used to treat
proteinuria [24,25]. The inhibition of HPSE activity reported HS levels
toward the normal amount only partially meaning that heparanase
regulates theHS turnover not only through its endoglycosidasic activity.
Consecutively to this fact, and that BSA and AGE increase the HPSE
intracellular protein amount, we supposed that heparanase could
regulate the different levels of HSPGs core proteins too, so we analyzed
the effect of albumin and glycated albumin and HPSE silencing on the
PTEC levels of syndecan-1 (one of the HSPG most abundant in PTECs).
Syndecan-1 core protein and gene expression were reduced by
albumin and glycated albumin in HK2 wt and HEK293 cells, but not in
HPSE silenced cells. In untreated HPSE silenced cells, moreover,
syndecan-1 gene transcription and protein levels were up-regulated
by comparison with wt cells. This means that HPSE in the proximal
tubular cells reduces HS levels also as a result of the downregulation
of syndecan-1.
It was previously reported that a direct relationship exists in
myeloma cells between HPSE and syndecan-1 shedding and gene
transcription [26–28]. Our results contrast with such ﬁndings, probably
because of the very different origin of the two types of cell considered.
Our data show that, in tubular cells at least, the inverse
relationship observed between HS levels and HPSE activity depends
also on a transcriptional activity of the molecule than on a simple
post-transcriptional, extracellular endoglycosidase activity, as previ-
ously postulated.
In conclusion, we show that stimulating PTEC with albumin and
AGE induces changes in heparanase-1 expression that may be
relevant to the progression of chronic nephropathies, including DN,
by various mechanisms. For a start, the increased HPSE endoglyco-
sidase activity could alter ECM turnover; secondly, by decreasing HS
on the cell membrane HSPGs, it may modify cell–cell and cell–matrix
crosstalk; thirdly, by regulating syndecan-1 expression, the intracel-
lular overexpression of HPSE could impair the activity of growth
factors such as FGF2 (and possibly others too). Experiments are
underway to investigate these issues.
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